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Aim: Drug-induced gingival overgrowth has a multifactorial nature and the pathogenesis
is still uncertain. It has been suggested that Nitric Oxide (NO) might play a role in the
pathogenesis of drug-induced gingival overgrowth due to the contribution of NO to
immune response and matrix degradation. NO levels in biological fluids have been used
as a diagnostic biomarker in many diseases. The aim of this study is to determine whether
NO levels in plasma, saliva, and gingival crevicular fluid (GCF) can serve as a potential
biomarker for the evaluation of drug-induced gingival overgrowth risk.
Materials and Methods: A total of 104 patients, receiving cyclosporine A (n = 35),
phenytoin (n = 25), nifedipine (n = 26), or diltiazem (n = 18) participated in the study.
The amount of gingival overgrowth was evaluated with two indices and was given as
percentage. Periodontal clinical parameters including plaque index (PI), gingival index
(GI), gingival bleeding time index (GBTI), and probing depth (PD) were also assessed.
Saliva, GCF, and plasma samples were obtained from each participants. Nitrite and
nitrate levels in saliva, GCF, and plasma were analyzed by Griess reagent.
Results: Salivary nitrite and nitrate levels in responders were significantly higher than
those in non-responders in only phenytoin group (p < 0.05). Nitrite and nitrate levels
of gingival crevicular fluid and plasma did not significantly differ between responders
and non-responders in all study groups (p > 0.05). Salivary nitrite levels exhibited a
significant correlation with PD, GBTI, severity of gingival overgrowth (%GO), and GCF
volume (p < 0.05). Additionally, a strong positive correlation was detected between saliva
and plasma nitrate levels (p < 0.005). However, both nitrite and nitrate levels in GCF and
plasma demonstrated no significant correlation with clinical parameters, GO severity, and
GCF volume (p > 0.05).
Conclusion: Salivary nitrite and nitrate levels could be used as periodontal disease
biomarkers in phenytoin induced gingival overgrowth, and that saliva seems to have
a better diagnostic potential than GCF and plasma for the evaluation of drug-induced
gingival overgrowth risk. However, when all drug groups were considered, saliva nitrite
and nitrate levels could not be used as a biomarker for drug-induced gingival overgrowth.
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INTRODUCTION
Drug-induced gingival overgrowth is a well-known side effect
of anticonvulsant phenytoin, immunosupressant cyclosporine A
(CsA), and antihypertensive calcium channel blockers. Although
the structural characteristics and pharmacologic effects of each
of these drugs are different, all of them can cause gingival
overgrowth that generally has a similar clinical and histological
appearance. The overgrowth normally begins at the interdental
papillae and is usually confined to the attached gingiva, but it may
extend coronally and interfere with the occlusion, mastication
and speech, and may also compromise proper plaque control
(Marshall and Bartold, 1999). The prevalence rate of gingival
overgrowth is about 50% for phenytoin (Güncü et al., 2006)
and 25–30% for CsA (Boltchi et al., 1999). This prevalence
rate in patients treated with calcium channel blockers varies
widely from 10 to 50% (Ellis et al., 1999; Güncü et al.,
2007).
Not all patients receiving these drugs develop gingival
overgrowth and the severity of overgrowth varies between
patients. Although, many clinical and laboratory studies have
been performed to clarify the underlying pathogenic mechanisms
responsible for drug-induced gingival overgrowth, the etiology
remains still undisclosed. Many risk factors including poor
plaque control, gender, age of the patient, drug dosage,
pharmacokinetic variables, and genetic predisposition have been
identified in a number of studies, but it is not possible to
determine the patients at high risk for developing gingival
overgrowth (Seymour et al., 2000).
The essential feature of drug-induced gingival overgrowth
is an increase in the connective tissue matrix and it results
from disturbance of the intricate balance between synthesis and
degradation of the extracellular matrix of the gingival tissues.
Some of the suggested factors responsible for this imbalance
are cytokines, inflammatory mediators, and growth factors
(Trackman and Kantarci, 2004; Chae et al., 2006; Kantarci et al.,
2006).
Nitric oxide (NO) is a gaseous free radical generated
from the conversion of L-arginine to L-citrulline by nitric
oxide synthase (NOS) (Jenkins et al., 1995). Three distinct
isoforms of NOS are known and identified as endothelial
NOS (eNOS), neuronal NOS (nNOS), and inducible NOS
(iNOS). eNOS and nNOS release small amounts of NO for
a short period of time following receptor stimulation and
they play an important role in regulation of physiological
processes including platelet aggregation, vascular relaxation,
and immune modulation. iNOS produces large amount of
NO, and is expressed in response to bacterial endotoxins and
cytokines, such as interleukin-1β and TNF-α (Forstermann
et al., 1994; Lyons, 1995). Distinct from eNOS and nNOS,
iNOS is considered to act in pathological conditions and
plays a detrimental role in the regulation of inflammatory
reactions. These NO-mediated detrimental effects probably
occur in combination with the action of metalloproteinases
and collagenases, produced by activated macrophages,
polymorphonuclear cells, and fibroblasts (Kröncke et al.,
1997; Kendall et al., 2001).
It has been shown that NO takes part in the etiopathogenesis
of many diseases, including periodontal disease (Ohashi et al.,
1999; Batista et al., 2002). Increased production of NO can
cause destruction of periodontal tissues (Batista et al., 2002).
Based on the role of NO on both immune response and matrix
degradation in the periodontal environment, it can be speculated
that NO may play an important role in the pathogenesis of
drug-induced gingival overgrowth. However, only few animal
and clinical studies have investigated the relationship between
NO and drug-induced gingival overgrowth (Fu et al., 2000;
Gau et al., 2005; Rezaie et al., 2005; Gürkan et al., 2009). Fu
et al. (2000) reported a decrease in gingival dimensions of CsA-
fed rats after NO substrate (L-arginine) treatment compared to
controls. In another animal study, Gau et al. (2005) demonstrated
that CsA-treated rats have increased plasma nitrite/nitrate levels
compared to control rats. In a recent study, Gürkan et al. (2009)
showed higher iNOS and eNOS immunostaining in connective
tissues from patients in the gingivitis and CsA induced gingival
overgrowth groups compared to healthy and subjects without
gingival overgrowth. However, no intergroup differences were
reported regarding nitrite/nitrate levels in gingival crevicular
fluid (GCF). There is no clinical human study evaluating the
relation of salivary nitrite and nitrate levels to drug-induced
gingival overgrowth in the literature. There is only one study
conducted on rats, in which the relation of nitric oxide
to nifedipine-induced gingival overgrowth and salivary gland
function was assessed. It was suggested that nitric oxide mediated
positive signal-transduction mechanisms in salivary glands may
play an important role in nifedipine-induced gingival overgrowth
(Rezaie et al., 2005).
Due to its reactivity and short half-life, direct measurements
of NO from tissues and biological fluids are hard to perform.
Although NO metabolites have a very short life, nitrite and
nitrate are the relatively stable end products of NO oxidation
(Lappin et al., 2000; Ugar-Cankal and Ozmeric, 2006). The
total levels of nitrite and nitrate in biological fluids are
generally used for adequate monitoring of the NO synthesis
(Moshage et al., 1995). Based on the findings that showed
a marked increase in NO synthesis in overgrown gingiva,
measuring nitrite and nitrate levels in saliva, GCF, and plasma
might be useful to understand the etiopathogenesis of drug-
induced gingival overgrowth. To the best of our knowledge,
there is no study evaluating the association of nitrite and
nitrate levels in saliva, plasma, and GCF with drug-induced
gingival overgrowth. Drug-induced gingival overgrowth may
constitute speech, mastication, hygienic, and aesthetic problems.
Thus, early diagnosis of drug-induced gingival overgrowth is
very important and it needs to have a diagnostic biological
marker to determine the risk of developing drug-induced
gingival overgrowth in patients receiving these drugs, before the
occurrence of gingival overgrowth. Therefore, the present study
was conducted to evaluate nitrite and nitrate levels in plasma,
saliva, and GCF from responders and non-responders treated
with either CsA, phenytoin, nifedipine, or diltiazem, and to
determine whether NO levels in plasma, saliva, and GCF can
serve as a potential biomarker for the evaluation of drug-induced
gingival overgrowth risk.
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MATERIALS AND METHODS
Study Population and Design
This research study was conducted at the Department of
Periodontology, Hacettepe University between February 2010
and September 2013. A total of 104 Turkish patients (50 male, 54
female) were included in the study. The study groups consisted of
35 renal transplant patients receiving CsA, 25 patients receiving
phenytoin, 26 patients receiving nifedipine, and 18 patients
receiving diltiazem therapy. Patients participated in this study
were obtained from outpatients attending the Department of
Nephrology, Neurology, and Cardiology, Faculty of Medicine,
Hacettepe University. Only patients receiving one of these drugs
(including CsA, phenytoin, nifedipine, and diltiazem) in regular
doses for at least 6 months were included in the study. The
presence of all maxillary and mandibular anterior teeth was also
required. Pregnant women, subjects with systemic diseases such
as diabetes mellitus or any other form of systemic inflammatory
involvement, patients who have mouth breath and restorative
crowns at anterior regions, and used any antibiotics or received
periodontal treatment within the last 6 months and who also
received one more drug leading to gingival overgrowth were
excluded from the study. Due to the fact that NO levels could
be affected by smoking, smokers were not included in the
study. The protocol of the study was approved by the ethics
committee of the Hacettepe University. (#FON 07/15-1) Written
informed consent in accordance with the Declaration of Helsinki
was obtained from each patient prior to enrollment in the
study.
Clinical Parameters
Periodontal examinations were carried out on the upper and
lower six anterior teeth by one calibrated periodontal specialist
(ES) during the study period. Periodontal clinical parameters
including plaque index (PI; Löe, 1967), gingival index (GI;
Löe, 1967), probing depth (PD), and gingival bleeding time
index (GBTI; Nowicki et al., 1981) were recorded. Demographic
variables including age and gender were also recorded.
In order to assess the overgrowth of gingival tissues accurately,
alginate impressions were obtained from each patient and
gypsum individual models were created. Gingival overgrowth
was assessed on these individual models by performing
measurements in vertical and horizontal dimensions. Vertical
measurements were performed according to the Miller and
Damm index (1992). Briefly, the height of the gingival tissue
was measured from the cemento-enamel junction (CEJ) to the
free gingival margin. The following grades were scored in six
points around each tooth on maxillary and mandibular anterior
region: 0 = normal gingiva; 1 = minimal enlargement (≤2mm
in size); 2 = moderate enlargement (2–4mm in size); and
3 = severe enlargement (nodular growth >4mm). Horizontal
gingival overgrowth wasmeasured in the buccal-lingual direction
of all interdental papillae of maxillary and mandibular anterior
teeth according to Miranda et al. (2001). The increase in the
size of buccal and lingual papillae was measured from the
enamel surface to the outer papillary surface at the interdental
contact point. Horizontal measurements were assigned a score of
between 0 and 2, as follows: 0 = normal thickness (1 < mm);
1= thickness between 1 and 2mm; and 2= thickness more than
2mm.
The vertical and horizontal scores were calculated to
determine an overgrowth score for each gingival papillae. The
maximum overgrowth score obtained for each interdental unit
was five. Twenty interdental units were identified, giving a
maximum overgrowth score of 100 for a patient. Therefore, this
index could be expressed as a percentage (Thomason et al., 2005).
A score of 30% was determined as the critical value for gingival
overgrowth index. Patients were classified into two subgroups
(Seymour and Smith, 1991) as followed: patients with a gingival
overgrowth index of <30% were identified as non-responders
(GO–) and patients with a value of ≥30% were defined as
responders (GO+). The severity of GO was also determined with
this percentage.
GCF, Saliva, and Plasma Sampling
The participants were told not to eat any high nitrate foods
(e.g., spinach, beets, and other green leafy vegetables) at least
12 h before sampling due to the fact that it may affect the
study results. GCF samples were obtained from maxillary
anterior teeth. To avoid blood contamination and possible
stimulation of GCF flow during clinical measurements, samples
were collected before any other clinical recordings except the
PI. GCF samples were obtained by the technique described
by Rüdin et al. (1970). Prior to sampling, the respective
region was dried by isolation with cotton rolls and a 5-s
gentle air stream with a 90◦ angle to the tooth axis, and
supragingival plaque was eliminated with a curette. Standardized
strips were inserted 1mm into the sulcus and left for 30 s.
Papers with visible blood contaminations were discarded and
sampling was replicated from another site of the natural tooth
that was not sampled. To eliminate the risk of evaporation,
paper strips with GCF were immediately transported to a
previously calibrated electronic GCF measuring device for
volume determination. The GCF was measured electronically
in Periotron units, which were converted to micro liters (µl)
by MCCONVRT software (Software version 2.52, Oraflow Inc.,
Amityville, NY, USA). GCF samples were then placed in sterile
Eppendorf tubes and stored at−30◦C until the day of laboratory
analysis. A total of 10 paper strips with GCF were obtained
with this standardize technique from maxillary anterior six
teeth of each patient for detecting GCF nitrite and nitrate
levels.
After GCF collection, stimulated parotid saliva samples were
obtained from each patient using Lashley cup (Lashley, 1916)
during stimulation with 1% citric acid. Citric acid was applied
to the dorsum of the tongue, held there by the subject for 10 s
and 1ml of saliva was collected from each patient as described
in detail before (Francis et al., 2001). Saliva samples were then
placed in sterile Eppendorf tubes and stored at −80◦C until the
laboratory analysis.
After saliva collection, in order to determine the plasma nitrite
and nitrate levels, venous blood samples were collected into
lithium-heparin tubes. Blood samples were placed within 3min
into a refrigerated (4◦C) centrifuge and centrifuged at 4000 rpm
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for 10min according to standard procedures (Uzar et al., 2011).
After getting plasma, samples were frozen at −80◦C for later
analysis of plasma nitrite and nitrate concentrations.
Determination of Nitrite and Nitrate Levels
in GCF, Saliva, and Plasma
For the determination of nitrite and nitrate levels in GCF
samples, 300ml of phosphate buffer (50mM, pH: 7.4) was added
onto each sample and the samples were mixed vigorously for
the extraction of nitrite and nitrate into buffer. Nitrite and
nitrate content of the samples extracts was determined using
Griess reagent (Grisham et al., 1996). The sum of nitrate and
nitrite was measured by the same assay after reduction of nitrate
to nitrite with nitrate reductase from Aspergillus niger (Roche
Diagnostics, Mannheim, Germany). Nitrite and nitrate levels in
both saliva and plasma were determined by the same method
without any pretreatment. The nitrate concentrations were
calculated by subtracting the nitrite level from the total nitrite
level (nitrite + nitrate). This assay is in the routine research
analyze protocol of the laboratories of Hacettepe University
Faculty of Medicine Department of Biochemistry for more
than a decade and its sensitivity and specificity is being tested
routinely by the university staff, together with other routine tests.
However, commercial standards were implemented to confirm its
sensitivity and specificity in the present study.
STATISTICAL ANALYSIS
Statistical analysis was performed with (SPSS Inc.,Chicago,
IL; Serial number: 2Z7ZHN12FA70P1JXWYNCMWY5). The
normality of data was tested with Kolmogorov Smirnov test.
Mann Whitney U test was used to compare each clinical
or laboratory findings for individual drug group between
responders and non-responders. Spearman correlation test was
obtained to determine the interactions between laboratory and
clinical parameters for all participants. The differences between
the age groups were tested with Independent sample t-test, and
the distribution differences of gender was analyzed with chi-
square test interms of between responders and non-responders.
The confidence interval was set as 95%.
All patients participated in this study (n = 104) revealed
a power of 87.74% with a normal approximation method. A
difference in salivary nitrate levels between responders and
non-responders in phenytoin group can be detected at an alpha
level of 0.05, with a statistical power of 87.74%.
RESULTS
A total of 104 patients consisting of CsA group (n = 35),
phenytoin group (n = 25), nifedipine group (n = 26), and
diltiazem group (n = 18) were included in the study. The
demographic variables of groups including mean age and gender
ratio are presented in Table 1.
Patients in each drug group were divided into two subgroups
as responders (overgrowth index ≥30%) and non-responders
(overgrowth index <30%) according to gingival overgrowth
index. Out of 35 patients in CsA group, 13 (37.1%) were
identified as responders, those values in phenytoin, nifedipine,
and diltiazem groups were 11 (44%), 11 (42.3%), and 2 (11.1%),
respectively. The gingival overgrowth index was significantly
higher in responders in all drug groups, as expected (Table 2).
There were statistically no significant differences between
responders and non-responders in mean age and gender ratio
in all drug groups except for nifedipine. While the mean age
was similar between subgroups in nifedipine group, there was a
significant difference in gender ratio (p < 0.05).
Clinical Periodontal Parameters
All clinical periodontal parameters including PI, GI, PD, and
GBTI were statistically higher in responders compared to non-
responders in all drug groups (p < 0.05), except for diltiazem
and nifedipine group (Table 3). In diltiazem group, these clinical
parameters were higher in responders but only the differences
in GBTI and GI reached statistically significance (p < 0.05). In
nifedipine group, all clinical periodontal parameters except PI
were statistically higher in responders (p < 0.05).
Nitrite and Nitrate Levels in Saliva, GCF,
and Plasma
Nitrite and nitrate levels of saliva, GCF, and plasma for the
subgroups of each study group are shown on Table 3. Salivary
nitrite and nitrate levels (µM) did not differ significantly between
responders and non-responders in all study groups, except for
phenytoin group. In phenytoin group, salivary nitrite and nitrate
levels in responders were significantly higher than those in non-
responders (p < 0.05). Nitrite and nitrate levels of GCF (nmol)
TABLE 1 | Demographic variables of study population.
Phenytoin CsA Nifedipine Diltiazem
(n = 25) (n = 35) (n = 26) (n = 18)
GO+ GO− GO+ GO− GO+ GO− GO+ GO−
(n = 11, 44%) (n = 14, 56%) (n = 13, 37.1%) (n = 22, 62.9%) (n = 11, 42.3%) (n = 15, 57.7%) (n = 2, 11.2%) (n = 16, 88.8%)
Age 40.1 ± 12.2 47.7 ± 16.2 35.3 ± 9.6 41.0 ± 9.7 51.1 ± 8.9 50.3 ± 9.1 53.5 ± 4.9 57.5 ± 9.6
Gender
Male 6 8 5 13 7 3 1 7
Female 5 6 8 9 4 12 1 9
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TABLE 2 | Clinical periodontal parameters in all groups.
Clinical
Periodontal
Parameters
Phenytoin CsA Nifedipine Diltiazem
(n = 25) (n = 35) (n = 26) (n = 18)
GO+ GO− GO+ GO− GO+ GO− GO+ GO−
PD 2.26± 0.57* 1.45±0.51 2.52±0.49* 1.45± 0.32 2.28± 1.02* 1.39± 0.38 2.46± 0.83 1.49± 0.33
PI 1.05± 0.58* 0.41±0.36 1.52±0.54* 0.62± 0.48 0.90± 0.63 0.56± 0.46 1.22± 0.74 0.59± 0.44
GI 1.62± 0.62* 0.88±0.52 2.04±0.38* 0.83± 0.61 1.64± 0.41* 0.79± 0.57 1.82± 0.25* 0.87± 0.36
GBTI 2.24± 0.91* 1.28±0.75 2.80±0.25* 1.17± 0.98 2.29± 0.55* 1.08± 1.07 2.75± 0.35* 1.10± 0.73
%GO 53.0± 11.93* 17.42±7.41 53.84±17.19* 18.36± 5.99 44.81± 12.2* 20.13± 6.05 33.00± 2.82* 18.81± 5.77
GCF V(µl) 0.94± 0.56 0.78±0.69 1.70±0.99* 0.74± 0.44 1.24± 0.71 1.00± 0.69 1.61± 0.26* 0.92± 0.39
PD, probing depth; PI, plaque index; GI, gingival index; GBTI, gingival bleeding time index; %GO, percentage of gingival overgrowth; GCF V, Volume of gingival crevicular fluid. *p <
0.05.
TABLE 3 | Nitrite and nitrate levels in saliva, plasma, and in GCF.
Phenytoin CsA Nifedipine Diltiazem
(n = 25) (n = 35) (n = 26) (n = 18)
GO+ GO− GO+ GO− GO+ GO− GO+ GO−
Saliva nitrite
level (µM)
7.08± 6.82* 2.90±2.36 7.44± 6.16 4.75± 3.42 4.87± 4.13 6.18± 5.84 3.60±1.81 4.96±4.07
Saliva nitrate
level (µM)
474± 37.17* 421.30±47.23 456.72± 54.05 478.69± 52.85 475.65± 55.96 430.63± 65.02 372.23±79.26 424.09±47.78
Plasma nitrite
level (µM)
4.33± 4.69 3.13±1.76 4.30± 3.15 2.60± 2.17 3.74± 2.82 3.00± 2.54 6.16±4.89 4.84±3.76
Plasma nitrate
level (µM)
27.89± 9.49 26.77±10.58 32.24± 18.60 42.89± 20.43 32.45± 7.18 26.21± 7.90 25.65±12.11 27.22±12.97
GCF nitrite
level (nmol)
6.39± 3.64 5.12±4.72 7.51± 4.38 9.17± 5.07 7.27± 5.39 6.21± 4.94 7.94±3.11 4.28±2.91
GCF nitrate
level (nmol)
226.22± 47.57 253.96±75.61 215.91± 64.58 221.01± 49.20 289.09± 47.78 288.83± 64.40 231.93±34.02 253.70±53.65
*p < 0.05.
and plasma (µM) did not significantly differ between responders
and non-responders in all study groups (p > 0.05).
Correlations between saliva, GCF, and plasma nitrite/nitrate
levels, periodontal clinical parameters, severity of GO, and GCF
volume were presented in Table 4. Salivary nitrite level exhibited
a significant correlation with PD, GBTI, severity of GO (%GO),
and GCF volume (p < 0.05). There was no significant correlation
between salivary nitrate level and periodontal clinical parameters,
except PD. A strong positive correlation was detected between
salivary and plasma nitrate levels (p < 0.005). There was a
negative significant correlation between nitrite and nitrate levels
in GCF (p < 0.05). Both nitrite and nitrate levels in GCF
and plasma demonstrated no significant correlation with clinical
parameters, GO severity, and GCF volume (p > 0.05).
DISCUSSION
To examine the role of NO in the pathogenesis of drug-induced
gingival overgrowth and also to determine whether NO levels in
plasma, saliva, and GCF can serve as a potential biomarker for
the evaluation of drug-induced gingival overgrowth risk, nitrite
and nitrate levels in saliva, GCF, and plasma were evaluated in
patients receiving either CsA, phenytoin, nifedipine, or diltiazem
therapy. To the best of our knowledge, this is the first study
that has evaluated the association of plasma, saliva, and GCF
nitrite/nitrate levels with drug-induced gingival overgrowth in
patients receiving either CsA, phenytoin, nifedipine, or diltiazem
therapy.
Although the pathogenesis of drug-induced gingival
overgrowth is still uncertain, it is characterized by excessive
deposition of extracellular matrix reflecting both elevated
synthesis and reduced degradation of matrix components
(Seymour et al., 1996). Fibroblasts are well-known to play
a critical role in collagen synthesis and connective tissue
turnover. The expression of iNOS has been demonstrated
in human dermal fibroblasts (Wang et al., 1996). And, it
has been reported that iNOS expression and NO production
were elevated in keloid scar tissue which is characterized by
excess collagen deposition (Hsu et al., 2006). Furthermore,
exposure of fibroblasts to exogenous NO resulted in increased
expression of collagen in a dose dependent manner (Hsu
et al., 2006). Similar to these findings, increased iNOS enzyme
activities were detected in overgrown gingiva from patients
taking CsA (Gürkan et al., 2009). Additionally, iNOS is
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 December 2015 | Volume 5 | Article 87
Sukuroglu et al. Nitric Oxide in Gingival Overgrowth
T
A
B
L
E
4
|
C
o
rr
e
la
ti
o
n
s
b
e
tw
e
e
n
n
it
ri
te
/n
it
ra
te
le
v
e
ls
a
n
d
c
li
n
ic
a
l
p
e
ri
o
d
o
n
ta
l
p
a
ra
m
e
te
rs
in
w
h
o
le
p
o
p
u
la
ti
o
n
.
P
D
P
I
G
B
T
I
G
I
%
G
O
G
C
F
v
o
lu
m
e
S
a
li
v
a
ry
n
it
ri
te
S
a
li
v
a
ry
n
it
ra
te
P
la
s
m
a
n
it
ri
te
P
la
s
m
a
n
it
ra
te
G
C
F
n
it
ri
te
G
C
F
n
it
ra
te
S
a
liv
a
ry
r
=
0
.2
7
0
r
=
0
.1
8
1
r
=
0
.2
0
2
r
=
0
.1
9
0
r
=
0
.2
5
6
r
=
0
.1
9
9
–
r
=
−
0
.0
1
0
r
=
−
0
.0
0
2
r
=
−
0
.0
6
3
r
=
0
.0
0
0
r
=
−
0
.1
2
0
N
itr
ite
p
=
0
.0
0
6
*
p
=
0
.0
6
7
p
=
0
.0
4
0
*
p
=
0
.0
5
3
p
=
0
.0
0
9
*
p
=
0
.0
4
3
*
p
=
0
.9
2
3
p
=
0
.9
8
7
p
=
0
.5
2
7
p
=
0
.9
9
6
p
=
0
.2
2
6
S
a
liv
a
ry
r
=
0
.2
3
1
r
=
0
.1
2
1
r
=
0
.1
7
6
r
=
0
.1
8
1
r
=
0
.0
8
8
r
=
−
0
.0
3
7
r
=
−
0
.0
1
0
–
r
=
−
0
.1
6
8
r
=
0
.3
6
5
r
=
0
.0
3
3
r
=
−
0
.1
6
1
N
itr
a
te
p
=
0
.0
1
8
*
p
=
0
.2
2
2
p
=
0
.0
7
4
p
=
0
.0
6
6
p
=
0
.3
7
4
p
=
0
.7
1
1
p
=
0
.9
2
3
p
=
0
.0
8
9
p
=
0
.0
0
1
**
p
=
0
.7
4
0
p
=
0
.1
0
1
P
la
sm
a
r
=
0
.0
8
1
r
=
0
.0
2
3
r
=
0
.0
2
7
r
=
0
.0
5
3
r
=
0
.0
6
0
r
=
0
.0
3
0
r
=
−
0
.0
0
2
r
=
−
0
.1
6
8
–
r
=
−
0
.1
3
3
r
=
−
0
.0
8
5
r
=
−
0
.0
1
2
N
itr
ite
p
=
0
.4
1
4
p
=
0
.8
1
8
p
=
0
.7
8
7
p
=
0
.5
9
1
p
=
0
.5
4
8
p
=
0
.7
6
3
p
=
0
.9
8
7
p
=
0
.0
8
9
p
=
0
.1
7
8
p
=
0
.3
9
2
p
=
0
.9
0
1
P
la
sm
a
r
=
0
.1
1
3
r
=
0
.0
2
2
r
=
−
0
.0
0
8
r
=
0
.0
2
9
r
=
−
0
.0
6
0
r
=
0
.0
7
1
r
=
−
0
.0
6
3
r
=
0
.3
6
5
r
=
−
0
.1
3
3
–
r
=
−
0
.0
2
5
r
=
−
0
.0
5
4
N
itr
a
te
p
=
0
.2
5
3
p
=
0
.8
2
6
p
=
0
.9
3
3
p
=
0
.7
7
2
p
=
0
.5
4
3
p
=
0
.4
7
4
p
=
0
.5
2
7
p
=
0
.0
0
1
**
p
=
0
.1
7
8
p
=
0
.8
0
2
p
=
0
.5
8
9
G
C
F
r
=
0
.1
6
3
r
=
0
.1
5
8
r
=
0
.1
4
8
r
=
0
.1
5
8
r
=
0
.0
0
3
r
=
−
0
.0
9
7
r
=
0
.0
0
0
r
=
0
.0
3
3
r
=
−
0
.0
8
5
r
=
−
0
.0
2
5
–
r
=
−
0
.2
6
7
N
itr
ite
p
=
0
.0
9
9
p
=
0
.1
0
9
p
=
0
.1
3
4
p
=
0
.1
0
9
p
=
0
.9
7
3
p
=
0
.3
2
7
p
=
0
.9
9
6
p
=
0
.7
4
0
p
=
0
.3
9
2
p
=
0
.8
0
2
p
=
0
.0
0
6
*
G
C
F
r
=
−
0
.1
4
1
r
=
−
0
.1
2
3
r
=
−
0
.1
2
7
r
=
−
0
.0
9
6
r
=
−
0
.0
2
5
r
=
0
.0
8
4
r
=
−
0
.1
2
0
r
=
−
0
.1
6
1
r
=
−
0
.0
1
2
r
=
−
0
.0
5
4
r
=
−
0
.2
6
7
–
N
itr
a
te
p
=
0
.1
5
4
p
=
0
.2
1
3
p
=
0
.1
9
9
p
=
0
.3
3
2
p
=
0
.8
0
3
p
=
0
.3
9
8
p
=
0
.2
2
6
p
=
0
.1
0
1
p
=
0
.9
0
1
p
=
0
.5
8
9
p
=
0
.0
0
6
*
P
D
,
p
ro
b
in
g
d
e
p
th
;
P
I,
p
la
q
u
e
in
d
e
x;
G
I,
g
in
g
iv
a
li
n
d
e
x;
G
B
T
I,
g
in
g
iv
a
lb
le
e
d
in
g
ti
m
e
in
d
e
x;
%
G
O
,
p
e
rc
e
n
ta
g
e
o
f
g
in
g
iv
a
lo
ve
rg
ro
w
th
;
G
C
F,
g
in
g
iv
a
lc
re
vi
c
u
la
r
flu
id
.
*p
<
0
.0
5
;
**
p
<
0
.0
0
5
.
largely expressed for sustained periods as a consequence of
induction by bacterial lipopolysaccharide and pro-inflammatory
mediators such as interleukin 1, tumor necrosis factor-α, and
interferon-γ, which are present in inflamed periodontal
tissues (Kendall et al., 2001). In drug-induced gingival
overgrowth patients due to the abundant gingiva, plaque
elimination becomes harder. When plaque accumulates
and could not be eliminated, gingival inflammation takes
place. Thus, prolonged production of NO by inflammatory
cells in gingiva may result in excess collagen deposition via
fibroblasts.
In the present study we did not collect whole saliva samples
from participants due to the fact that nitrite and nitrate
concentrations in whole saliva originate from sources other
than the glandular cells, such as GCF and intraoral bacteria.
Salivary nitrate is converted to salivary nitrite by oral bacteria
(Kleinbongard et al., 2003). Thus, we used pure stimulated
parotid saliva for analyzing saliva nitrite and nitrate levels.
In the present study, no significant differences were detected
according to age between responders and non-responders in each
drug groups. Although age has been suggested as a predisposing
factor associated with drug-induced gingival overgrowth (Hefti
et al., 1994; Somacarrera et al., 1994), in the present study no
significant differences were detected according to age among the
study groups for all the drug groups investigated. Similar to our
results, Ellis et al. (1999) have reported no relations between age
and drug-induced gingival overgrowth.
There were no significant differences in gender ratios between
responders and non-responders in all drug groups, except for
nifedipine group. In nifedipine group, males were found to be
more dominant in patients developing gingival overgrowth, as
previously shown before (Hattori et al., 1995; Tavassoli et al.,
1998). This difference can be explained with the alteration in
androgen metabolism in males.
All periodontal clinical parameters including PI, GI, GBTI,
and PD were significantly higher in responders in all drug groups
except for diltiazem group. These differences in periodontal
clinical parameters between responders and non-responders can
be explained by poor plaque control in responders due to the
gingival overgrowth. In diltiazem group, although all periodontal
clinical parameters were higher in responders, only the GI, GBTI,
and %GO scores were significantly different. The reason for the
lack of significant differences in PD and PI scores may be the
limited number of responders in this drug group.
A total of 104 patients were analyzed separately in four
groups according to drugs that patients were taking due to the
fact that these drugs may affect directly or indirectly the NO
metabolism. Patients receiving nifedipine or diltiazem were not
evaluated within the same group although both of the drugs have
been known as calcium channel blockers. Because it has been
reported that nifedipine had an inhibitory effect on induction of
NO synthesis, and also inhibited nitrite production in vascular
smooth muscle cells, mesangial cells, and cardiac myocytes.
However, diltiazem had no effect on nitrite formation in these
three cell types (Hattori et al., 1995). Like diltiazem, it has not
been demonstrated such an inhibitory effect of phenytoin on NO
production (Nagatomo et al., 2000). On the other hand, it was
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suggested that CsA could increase gingival iNOS expression (Gau
et al., 2005).
The results of the present study demonstrated a significant
difference in salivary nitrite and nitrate levels between responders
and non-responders in phenytoin group. However, nitrite and
nitrate levels in saliva did not differ significantly between
responders and non-responders in other drug groups. Similarly,
nitrite and nitrate levels in GCF and plasma were not significantly
different between subgroups in all study groups.
Although, there have been many studies evaluating the nitrite
and nitrate levels of biological fluids as a diagnostic biomarker in
oral diseases and periodontitis, only few of them have focused
on NO contribution to drug-induced gingival overgrowth. Fu
et al. (2000) reported that significantly decreased dimensions
of gingival tissues from CsA fed rats receiving L-arginine (NO
substrate) or L-NAME (NO blocker) compared to control rats.
They also found that plasma nitrite/nitrate concentrations were
higher in L-arginine supplement. In another study conducted
on rats, it was reported that significantly greater iNOS enzyme
activities in gingival tissues obtained from CsA-treated rats
than from control rats (Gau et al., 2005). Similarly, the plasma
nitrite/nitrate levels were higher in CsA-treated rats than those
in control group. In these two studies conducted on rats, nitrite
and nitrate were reduced to NO and depicted as total nitrite and
nitrate concentration, however nitrite and nitrate concentrations
were not reported separately in studied groups. In contrast to
the results of these studies, we did not found any significant
differences in plasma nitrite and nitrate concentrations between
responders and non-responders in all drug groups. In a clinical
study, iNOS production significantly increased in connective
tissue from gingivitis and CsA-induced gingival overgrowth
groups (Gürkan et al., 2009). However, no intergroup differences
were found regarding nitrite/nitrate levels in GCF. It was
suggested that the reason of this situation might be related to
the higher dilution of nitrite and nitrate by GCF volume, which
was clearly elevated in responders than non-responders. Another
reason might be environmental differences in oral cavity such as
composition of oral flora. In the present study, similar to these
results, we did not observe any significant difference in nitrite and
nitrate levels of GCF between responders and non-responders in
all groups.
In the present study, both nitrite and nitrate levels in
saliva were found to be significantly increased in responders in
phenytoin group. However, no significant differences in salivary
nitrite and nitrate levels were observed between responders and
non-responders in other drug groups. To the results of a clinical
study comparing the NO levels in saliva with the severity of
chronic periodontitis, NO levels in saliva increased with severity
of chronic periodontitis (Reher et al., 2007). On contrast to these
results, Topcu et al. (2014) suggested that nitrite in GCF is a
better periodontal disease marker than nitrate in GCF and those
in saliva. In another study of the same research group, a tendency
to increase in nitrite levels in GCF and peri-implant sulcular
fluid with the presence of gingival/peri-implant inflammation
was reported (Tözüm et al., 2007).
When the correlations between nitrite and nitrate levels in
GCF, saliva, and plasma, periodontal clinical parameters, GCF
volume and severity of GO are taken into account, the nitrite
level in saliva was found to be significantly correlated to PD and
GBTI scores, severity of GO and GCF volume. However, nitrate
levels in saliva significantly correlated only to PD score and
plasma nitrate level. On the contrary, no significant correlation
was found between periodontal clinical parameters, severity of
GO and nitrite/nitrate levels in plasma and GCF. Based on
these results, it can be suggested that nitrite and nitrate levels
in saliva, especially nitrite levels, are more powerful biomarkers
than those in plasma and GCF for evaluating drug-induced
gingival overgrowth risk. Similar to our results, in a clinical
study evaluating the diagnostic role of salivary and GCF nitrite,
nitrate and nitric oxide to distinguish healthy periodontium from
gingivitis and periodontitis, it was reported that detecting NO
biomarker and its end metabolites in saliva is of more value
to assess the periodontal health comparing to GCF (Poorsattar
Bejeh-Mir et al., 2014). We also found a significant positive
correlation between nitrate levels in saliva and plasma, as
previously shown before (Clodfelter et al., 2015). The positive
correlation between salivary nitrate and plasma nitrate might be
explained by the nitrate–nitrite–NO cycle (Lundberg et al., 2008).
Ingested nitrate enters the plasma and is taken back up from the
circulation by the salivary glands (Lundberg and Govoni, 2004;
Lundberg et al., 2008, 2009). Thus, nitrate levels in plasma and
saliva are interrelated.
Nitrite and nitrate levels in biological fluids such as plasma,
GCF, and saliva might be useful for diagnosis and monitoring
of many diseases, including periodontal disease. However, nitrite
and nitrate levels in these biological fluids do not always
demonstrate the activity and expression of NOS in tissues. It is
well-known that NO is produced from L-arginine by NOS in cells
(Jenkins et al., 1995). On the other hand, cigarette smoking, oral
medicines and supplements that contain nitro-substances, and
foods such as spinach, beets, and other green leafy vegetables are
exogenous sources of systemic NO (Jobgen et al., 2007). Thus, it is
not appropriate to measure nitrite and nitrate levels in biological
fluids as an indicator of NO synthesis when these factors are not
taken into account.
The most effective treatment of drug-induced gingival
overgrowth is substitution of these medications by the patient’s
physician. The resolution of gingival lesions may take from 1
to 8 weeks depending on the severity of overgrowth (Khocht
and Schneider, 1997). However, not all patients respond to this
treatment modality, especially those with long-standing gingival
overgrowth (Harel-Raviv et al., 1995). Thus, surgical intervention
is commonly required to solve the aesthetic and functional
problems caused by gingival overgrowth.
CONCLUSION
Within the limitations of the present study, nitrite and nitrate
levels in saliva could be used as periodontal disease biomarkers
in phenytoin-induced gingival overgrowth. And also, saliva has
a better diagnostic potential than GCF and plasma for the
evaluation of drug-induced gingival overgrowth risk. However,
when all drug groups were considered, salivary nitrite and nitrate
levels could not be used as a biomarker for drug-induced gingival
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overgrowth. Additionally, present interpretations require caution
due to the limited number of subjects evaluated in drug groups.
Further studies including higher subjects will be needed to clarify
the use of salivary nitrite/nitrate levels as a biomarker for drug-
induced gingival overgrowth.
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